These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 16166276)

  • 1. Marrying immunotherapy with chemotherapy: why say IDO?
    Muller AJ; Prendergast GC
    Cancer Res; 2005 Sep; 65(18):8065-8. PubMed ID: 16166276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation.
    Munn DH
    Curr Opin Immunol; 2006 Apr; 18(2):220-5. PubMed ID: 16460921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indoleamine 2,3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer Immunotherapy.
    Yentz S; Smith D
    BioDrugs; 2018 Aug; 32(4):311-317. PubMed ID: 29980987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.
    Muller AJ; DuHadaway JB; Donover PS; Sutanto-Ward E; Prendergast GC
    Nat Med; 2005 Mar; 11(3):312-9. PubMed ID: 15711557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors.
    Muller AJ; Malachowski WP; Prendergast GC
    Expert Opin Ther Targets; 2005 Aug; 9(4):831-49. PubMed ID: 16083346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor immune escape mediated by indoleamine 2,3-dioxygenase.
    Zamanakou M; Germenis AE; Karanikas V
    Immunol Lett; 2007 Aug; 111(2):69-75. PubMed ID: 17644189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors.
    Muller AJ; Scherle PA
    Nat Rev Cancer; 2006 Aug; 6(8):613-25. PubMed ID: 16862192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies.
    Selvan SR; Dowling JP; Kelly WK; Lin J
    Curr Cancer Drug Targets; 2016; 16(9):755-764. PubMed ID: 26517538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy.
    Brochez L; Chevolet I; Kruse V
    Eur J Cancer; 2017 May; 76():167-182. PubMed ID: 28324751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IDO inhibitors move center stage in immuno-oncology.
    Sheridan C
    Nat Biotechnol; 2015 Apr; 33(4):321-2. PubMed ID: 25850038
    [No Abstract]   [Full Text] [Related]  

  • 11. Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model.
    Yoshida N; Ino K; Ishida Y; Kajiyama H; Yamamoto E; Shibata K; Terauchi M; Nawa A; Akimoto H; Takikawa O; Isobe K; Kikkawa F
    Clin Cancer Res; 2008 Nov; 14(22):7251-9. PubMed ID: 19010841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease.
    Macchiarulo A; Camaioni E; Nuti R; Pellicciari R
    Amino Acids; 2009 Jul; 37(2):219-29. PubMed ID: 18612775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape.
    Katz JB; Muller AJ; Prendergast GC
    Immunol Rev; 2008 Apr; 222():206-21. PubMed ID: 18364004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comment on "Reduced cytotoxic function of effector CD8+ T cells is responsible for indoleamine 2,3-dioxygenase-dependent immune suppression".
    Sørensen RB; thor Straten P; Andersen MH
    J Immunol; 2009 Nov; 183(10):6040. PubMed ID: 19890063
    [No Abstract]   [Full Text] [Related]  

  • 15. Indoleamine 2,3-dioxygenase and immune tolerance in ovarian cancer.
    Ino K
    Curr Opin Obstet Gynecol; 2011 Feb; 23(1):13-8. PubMed ID: 20930628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy.
    Brochez L; Kruse V; Schadendorf D; Muller AJ; Prendergast GC
    Front Immunol; 2021; 12():789473. PubMed ID: 34938297
    [No Abstract]   [Full Text] [Related]  

  • 17. Accelerated rejection of the second transplants of immunogenic tumor in mice under inhibition of indoleamine 2,3-dioxygenase activity by ethyl pyruvate.
    Vasilyeva ED; Kaledin V; Nikolin VP; Popova NA; Kirilyuk IA; Grigor'ev IA
    Exp Oncol; 2012; 34(1):66-8. PubMed ID: 22453153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells.
    Lee SY; Choi HK; Lee KJ; Jung JY; Hur GY; Jung KH; Kim JH; Shin C; Shim JJ; In KH; Kang KH; Yoo SH
    J Immunother; 2009 Jan; 32(1):22-8. PubMed ID: 19307990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA.
    Yen MC; Lin CC; Chen YL; Huang SS; Yang HJ; Chang CP; Lei HY; Lai MD
    Clin Cancer Res; 2009 Jan; 15(2):641-9. PubMed ID: 19147770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.
    Hou DY; Muller AJ; Sharma MD; DuHadaway J; Banerjee T; Johnson M; Mellor AL; Prendergast GC; Munn DH
    Cancer Res; 2007 Jan; 67(2):792-801. PubMed ID: 17234791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.